Compare SHAK & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SHAK | NRIX |
|---|---|---|
| Founded | 2004 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.5B |
| IPO Year | 2014 | 2020 |
| Metric | SHAK | NRIX |
|---|---|---|
| Price | $58.07 | $23.18 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 26 | 12 |
| Target Price | ★ $117.29 | $30.50 |
| AVG Volume (30 Days) | 1.9M | ★ 1.9M |
| Earning Date | 05-07-2026 | 04-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 354.17 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,445,306,000.00 | $76,987,000.00 |
| Revenue This Year | $16.58 | N/A |
| Revenue Next Year | $15.07 | $48.05 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 15.38 | ★ 99.31 |
| 52 Week Low | $51.60 | $8.20 |
| 52 Week High | $142.20 | $25.09 |
| Indicator | SHAK | NRIX |
|---|---|---|
| Relative Strength Index (RSI) | 47.96 | 61.64 |
| Support Level | $52.44 | $14.63 |
| Resistance Level | $61.74 | $24.98 |
| Average True Range (ATR) | 2.52 | 1.25 |
| MACD | 0.88 | -0.23 |
| Stochastic Oscillator | 55.18 | 50.58 |
Shake Shack Inc is a roadside burger stand. It serves a classic American menu of premium burgers, hot dogs, crispy chicken, frozen custard, crinkle-cut fries, shakes, beer, wine, and more. The company's burgers are made with a whole-muscle blend of all-natural, hormone and antibiotic-free Angus beef, ground fresh daily, cooked to order, and served on a non-genetically modified organism (GMO) potato bun. Its menu focuses on food and beverages, crafted from a range of classic American foods. The company serves draft Root Beer, seasonal freshly-squeezed lemonade, organic fresh-brewed iced tea, cold brew coffee, organic apple juice, and Shack20 bottled water. Geographically, the company generates the majority of its revenue from the United States.
Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.